Reata Pharmaceuticals (NASDAQ:RETA) had its price target upped by research analysts at Robert W. Baird from $162.00 to $245.00 in a research note issued on Tuesday, The Fly reports. The brokerage currently has a “positive” rating on the stock. Robert W. Baird’s price objective points to a potential upside of 23.17% from the company’s current price.
Other research analysts have also issued research reports about the stock. Zacks Investment Research lowered shares of Reata Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, October 16th. LADENBURG THALM/SH SH reissued a “positive” rating and set a $239.00 price objective (up previously from $133.00) on shares of Reata Pharmaceuticals in a research note on Wednesday, October 16th. Leerink Swann set a $230.00 price objective on shares of Reata Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, October 15th. BidaskClub raised shares of Reata Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 2nd. Finally, Cantor Fitzgerald lifted their price objective on shares of Reata Pharmaceuticals from $180.00 to $250.00 and gave the stock an “overweight” rating in a research note on Monday, November 4th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $247.63.
Shares of RETA stock traded down $4.53 during mid-day trading on Tuesday, reaching $198.91. The company’s stock had a trading volume of 877,400 shares, compared to its average volume of 645,809. The firm’s 50-day moving average is $152.87 and its two-hundred day moving average is $102.51. Reata Pharmaceuticals has a 1-year low of $47.50 and a 1-year high of $217.47. The company has a market cap of $5.64 billion, a P/E ratio of -69.31 and a beta of 2.75.
In other Reata Pharmaceuticals news, insider Elaine Castellanos sold 2,000 shares of the firm’s stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $85.00, for a total transaction of $170,000.00. Following the sale, the insider now directly owns 4,138 shares in the company, valued at approximately $351,730. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO James Warren Huff sold 63,000 shares of the firm’s stock in a transaction that occurred on Friday, September 27th. The stock was sold at an average price of $86.61, for a total transaction of $5,456,430.00. Following the sale, the chief executive officer now owns 164,157 shares in the company, valued at $14,217,637.77. The disclosure for this sale can be found here. Insiders have sold a total of 101,000 shares of company stock worth $10,661,430 over the last 90 days. Corporate insiders own 34.40% of the company’s stock.
A number of hedge funds have recently made changes to their positions in the business. Alta Advisers Ltd acquired a new stake in Reata Pharmaceuticals during the 3rd quarter worth approximately $12,897,000. BBVA USA Bancshares Inc. acquired a new stake in Reata Pharmaceuticals during the 3rd quarter worth approximately $321,000. Tower Research Capital LLC TRC raised its holdings in Reata Pharmaceuticals by 1,603.1% during the 3rd quarter. Tower Research Capital LLC TRC now owns 545 shares of the company’s stock worth $44,000 after buying an additional 513 shares during the period. First Trust Advisors LP raised its holdings in shares of Reata Pharmaceuticals by 12.2% in the third quarter. First Trust Advisors LP now owns 58,236 shares of the company’s stock valued at $4,676,000 after purchasing an additional 6,319 shares during the last quarter. Finally, Russell Investments Group Ltd. acquired a new stake in shares of Reata Pharmaceuticals in the third quarter valued at approximately $200,000. Hedge funds and other institutional investors own 58.24% of the company’s stock.
Reata Pharmaceuticals Company Profile
Reata Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways that regulate cellular metabolism and inflammation. The company is developing Phase III clinical trial programs, including bardoxolone methyl (Bard) for the treatment of patients with chronic kidney disease caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; and omaveloxolone that is Phase II clinical trial for the treatment of patients with Friedreich's ataxia It is also developing RTA 901, which completed Phase 1 clinical trials for the treatment of orphan neurological indications; and RORgT Inhibitors that are in the preclinical development phase for the potential treatment of a range of autoimmune, inflammatory, and fibrotic diseases.
Further Reading: Why do companies issue monthly dividends?
Receive News & Ratings for Reata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.